Petros Pharmaceuticals, Inc. (PTPI) on Tuesday announced its strategic position following the FDA's recently approved final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" or ACNU. The rule facilitates Rx-to-OTC switches, allowing more prescription medications to be made available over the counter.
Petros has developed a proprietary technology platform that leverages AI and quantum computing to assist pharmaceutical companies in navigating the complex Rx-to-OTC switch process.
This platform could significantly benefit pharmaceutical companies by offering solutions that expand access and enhance the commercial viability of OTC medications.
The self-care market is valued at over $38 billion and is expected to grow at a 5.6% annual rate over the next decade, offering significant opportunities for Petros and its partners.
Petros aims to be a innovator in this emerging market by helping companies meet the FDA's requirements for Rx-to-OTC switches.
"We are excited to be at the forefront of this emerging sector," said Fady Boctor, President and Chief Commercial Officer of Petros Pharmaceuticals. "Our unique technology and ongoing FDA discussions position us as a key player in the Rx-to-OTC transition."
As of now, Petros continues to develop its SaaS platform, designed to support pharmaceutical companies in meeting FDA standards for the Rx-to-OTC switch process.
Currently, PTPI is trading at $0.45 up by 12.56%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.